Skip to content
2000
Volume 2, Issue 4
  • ISSN: 2666-7967
  • E-ISSN: 2666-7975

Abstract

The explanations behind the wide spreadability of coronavirus sickness (COVID-19) are not known properly in this world. Several clinical investigations have indicated that the BCG antibody impacts on the immune system and human sicknesses which take part in the host system to such an extent that numerous types of viral diseases are extensively diminished or reduced. Subsequently, it was also observed in different studies that the recurrence and seriousness of numerous microbial or viral diseases, including COVID-19, will be lower in few countries where BCG Immunization programs are carried out. Few clinical investigations proposed by the epidemiological data have shown that the BCG antibody has a valuable impact in the treatment of COVID-19. So the BCG immunization may be found valuable in the coming months, particularly in the countries, where mass BCG immunization is done. Further thorough BCG immunization clinical trial is required to establish the above findings and its clinical significance. In future, this investigation will concentrate on the BCG vaccine and it may forestall the event of SARS-CoV-2 contamination and its succession in the large population.

Loading

Article metrics loading...

/content/journals/covid/10.2174/2666796701999201005212124
2021-04-01
2025-12-16
Loading full text...

Full text loading...

/content/journals/covid/10.2174/2666796701999201005212124
Loading

  • Article Type:
    Review Article
Keyword(s): BCG vaccination; Coronavirus; COVID-19; epidemiological; immunization; pandemic
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test